151 related articles for article (PubMed ID: 7621247)
1. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
Brysch W; Magal E; Louis JC; Kunst M; Klinger I; Schlingensiepen R; Schlingensiepen KH
Cancer Gene Ther; 1994 Jun; 1(2):99-105. PubMed ID: 7621247
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
Alper O; Hacker NF; Cho-Chung YS
Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
[TBL] [Abstract][Full Text] [Related]
5. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
6. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.
Giani C; Casalini P; Pupa SM; De Vecchi R; Ardini E; Colnaghi MI; Giordano A; Ménard S
Oncogene; 1998 Jul; 17(4):425-32. PubMed ID: 9696035
[TBL] [Abstract][Full Text] [Related]
8. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides.
Bertram J; Killian M; Brysch W; Schlingensiepen KH; Kneba M
Biochem Biophys Res Commun; 1994 Apr; 200(1):661-7. PubMed ID: 7909438
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
Tari AM; Hung MC; Li K; Lopez-Berestein G
Oncogene; 1999 Feb; 18(6):1325-32. PubMed ID: 10022814
[TBL] [Abstract][Full Text] [Related]
10. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
Hwang MS; Yum YN; Joo JH; Kim S; Lee KK; Gee SW; Kang HI; Kim OH
Anticancer Res; 2001; 21(4A):2649-55. PubMed ID: 11724334
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
Roh H; Pippin J; Boswell C; Drebin JA
J Surg Res; 1998 Jun; 77(1):85-90. PubMed ID: 9698539
[TBL] [Abstract][Full Text] [Related]
13. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
Liu J; Spence MJ; Wallace PM; Forcier K; Hellström I; Vestal RE
Cell Growth Differ; 1997 Jun; 8(6):667-76. PubMed ID: 9186000
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
16. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells.
Abdel-Mageed A; Agrawal KC
Cancer Gene Ther; 1997; 4(3):199-207. PubMed ID: 9171939
[TBL] [Abstract][Full Text] [Related]
17. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
19. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha.
Kumar R; Mendelsohn J
Anticancer Res; 1994; 14(3A):1001-8. PubMed ID: 7915505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]